Abstract

Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of severe combined immunodeficient (SCID)/Beige and nonobese diabetic (NOD)/SCID/IL-2γ-receptor null (NSG) mice under a series of transplant conditions. Both models yielded stably transplantable xenografts at comparably high rates (~21% and ~19%, respectively). Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established, representing 25 unique patients. Most tumors yielding xenografts were "triple-negative" [estrogen receptor (ER)–progesterone receptor (PR)–HER2+; n = 19]. However, we established lines from 3 ER−PR−HER2+ tumors, one ER−PR−HER2−, one ER+PR+HER2−, and one "triple-positive" (ER+PR+HER2+) tumor. Serially passaged xenografts show biologic consistency with the tumor of origin, are phenotypically stable across multiple transplant generations at the histologic, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses as those observed clinically. Xenografts representing 12 patients, including 2 ER+ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis. Cancer Res; 73(15): 4885–97. ©2013 AACR.

Introduction

In translational breast cancer research, our ability to evaluate clinical responses of human tumors to new therapeutic agents is restricted experimentally. For example, we cannot evaluate the clinical response of a single treatment-naïve tumor to multiple candidate therapeutics. Furthermore, the number of in vivo preclinical human tumor models currently available remains limited, thus precluding conduct of xenograft-based "mouse clinical trials," reflecting the heterogeneity of human tumors using candidate therapeutic agents. These limitations severely compromise our ability to develop and test novel therapeutics, and to predict the best course of treatment for a given tumor subtype, and more importantly, an individual patient with breast cancer.

Historically, in vivo experimental therapeutic research has relied on either genetically engineered mouse models, or "xenograft" transplantation models, in which established human cancer cell lines are transplanted into immunocompromised host mice. However, while mouse models mutant for TP53 do show a high degree of heterogeneity, genetically engineered animal models do not fully recapitulate the full spectrum of...
human breast cancers (4). Similarly, a cell line represents only a single tumor type, and indeed only a single patient. Furthermore, most available cell lines have been maintained in culture for years, or decades, and it has been debated whether these cell lines still accurately reflect the biologic characteristics of the tumor of origin (5–7).

Early attempts to use primary breast cancer tissue xenografts [also known as patient-derived xenografts (PDX) models, or "tumorgrafts"] as experimental models met with limited success (1, 2, 5, 6, 8–12), with typical rates of stable transplantation being 10% or less. Most of these attempts used athymic (nude) or nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, which lack B- and T-cell function but retain innate cellular immunity [natural killer (NK) cells, macrophages etc.] frequently leading to elimination of tumor cells over time (13, 14). A vast majority of the stable xenografts produced have not expressed the estrogen receptor (ER)\textsuperscript{−}, but ER\textsuperscript{+} xenografts have recently begun to be reported (9, 11, 12, 15).

In a recent report, the efficiency of transplantation using normal human mammary epithelial cells (from reduction mammoplasty) was increased by "humanizing" the mammary fat pad of NOD/SCID mice via introducing an immortalized human fibroblast cell line, derived from a normal donor, into the mammary fat pad before transplantation (10). The influence of these human fibroblasts on the growth of patient-derived breast cancer was not tested. In any case, because these fibroblasts were derived from a normal patient rather than from the patient-matched tumors, the presence of such fibroblasts may alter tumor biology significantly.

We sought to circumvent some of these limitations by propagating human tumors as xenografts in SCID/Beige (SCID/Bg) immunocompromised mice, which were known to accept transplants of hematopoietic malignancies with higher efficiency than traditional immunocompromised models, and had not been used previously to establish breast cancer xenografts. SCID/Bg mice lack B-cell, T-cell, and NK cell function entirely, but show enhanced macrophage populations relative to wild-type mice (13, 14). Macrophages are required for mammary gland growth (16, 17) and immature myeloid cells of the macrophage lineage were recently shown to promote tumor invasion and metastasis (18). Three different transplantation conditions were compared and the optimal transplant condition also used to evaluate outgrowth rates in NOD/SCID/IL-2γ-receptor null (NSG) immunocompromised mice. Resulting stably transplantable xenografts were characterized with respect to expression of clinically relevant biomarkers and gene expression patterns (mRNA and protein), and a subset of patient/xenograft treatment responses, to lay the foundation for their use as preclinical models for breast cancer research.

Materials and Methods

Patient recruitment

Patients with breast cancer were recruited from clinics in the Baylor College of Medicine (BCM) Breast Center (Houston, TX) and Ben Taub General Hospital (Houston, TX) under Institutional Review Board-approved protocols. Most patients received initial core-needle biopsies at the time of diagnosis and again either during or after treatment. Surgical samples were also obtained whenever possible.

Establishment of xenografts

The study design is outlined in Supplementary Fig. S1. All mice were maintained and treated in accordance with the NIH Guide for the Care and Use of Experimental Animals with approval from the BCM Institutional Animal Care and Use Committee. A detailed surgical protocol was published elsewhere (19).

Pretreatment biopsy and posttreatment surgical specimens were received within an hour after excision. For fragment transplantation, samples were minced into approximately 1 mm\(^3\) fragments and transplanted directly into epithelium-free "cleared" fat pads (20) of recipient SCID/Bg (Charles River Laboratories), or NSG mice (Jackson Laboratories; \(n = 2\) per patient). Transplants were conducted under the following conditions: condition 1: unmanipulated host mice, condition 2: 17β-Estradiol supplementation (60-day release, 0.36 mg/pellet, Innovative Research of America, Cat.# SE-121), or condition 3: 17β-Estradiol supplementation with inclusion of 5 × 10\(^4\) immortalized normal human fibroblasts [passages 35–41; 1:1 unirradiated:irradiated cells (4 Gy), as described previously (10); fibroblasts generously provided by Dr. Charlotte Kuperwasser, Tufts University, Boston, MA]. Mice were palpated weekly and tumor growth measured using calipers. Conditions found to be optimal for SCID/Bg mice were then tested using NSG mice (condition 4).

We were also able to obtain a few samples from either pleural effusion or metastatic ascites. Fluid was centrifuged and cells resuspended in a volume of 10 to 50 μL, and injected into the cleared mammary fat pad using a Hamilton syringe. Xenografts derived from such samples were not included in the statistical analyses, but are included here for completeness of the collection.

Regardless of the source of tumor cells, when primary outgrowths reached 10 mm in diameter, or if glands were suspected of carrying small primary outgrowths, fragments were retransplanted into new hosts (\(n = 3–4\)) as secondary xenografts. If no overt tumor formation was observed by 30 weeks, glands were harvested and processed for histologic evaluation. Primary outgrowth take was defined as a surviving tissue fragment more than 1 mm in diameter and shown to be proliferative (Ki67 positivity). A xenograft line was defined as stable upon growth at transplant generation 3 (TG3).

Statistical analysis of clinical characteristics, biomarker expression, and outgrowth potential

The overall primary outgrowth and stable xenograft take rates were computed for each transplantation condition (Table 1) and compared using logistic regression. Clinical characteristics were summarized and compared across 4 different transplantation conditions using Fisher's exact test. Within each transplantation condition, primary outgrowth as well as stable take rate was compared by clinical characteristics using Fisher's exact test (Supplementary Table S1). There were a few patient samples appearing in both transplantation

---

Cancer Res; 73(15) August 1, 2013
Zhang et al.
conditions 2 and 3. We conducted a McNemar test to examine those overlapping samples and did not observe any significant difference. Thus, we analyzed the data as independent samples for different transplantation conditions.

**Xenograft characterization**

Xenografts were validated as unique by short tandem repeat (STR) DNA fingerprinting using the AmpFSTR Identifiler kit according to manufacturer’s instructions (Applied Biosystems Cat.# 4322888). The STR profiles were compared with known American Type Culture Collection (ATCC) fingerprints (ATCC.org) and to the Cell Line Integrated Molecular Authentication database version 0.1.200808 (http://bioinformatics.istge.it/clima/; ref. 21). The STR profiles of all xenograft lines were unique (Supplementary Table S2).

**Histologic evaluation of xenografts**

Transplanted glands/tumors were of H&E stained. Outgrowths were analyzed by immunohistochemistry for stability of expression of clinically-relevant biomarkers (ER, PR, HER2, Ki67; Ertz, Novocastra Laboratories Ltd., Cat.# NCL-ER-6F11; PR, DAKO, Cat.# M3568; HER2, NeoMarkers, Lab Vision Corporation, Cat.# RM-9103; Ki67, DAKO, Cat.# M7240) with positive controls. Additional biomarkers included human cytokeratin 19 (CK19; NeoMarkers, Lab Vision Corporation, Cat.# MS-198-P, 1:400), Cytokeratin 5/6 (Dako, Cat.# M7237 at a 1:100 dilution), EGF receptor (EGFR; pharmDx Kit, DAKO, Cat.# K1492, ready to use), and TP53 (Vector, Cat.# VP-P958, 1:1000 dilutions). Biomarker expression patterns were compared with the tumor of origin whenever possible, or with the clinical pathology report (Table 2 and Supplementary Table S3).

**Intrinsic subtype analysis**

Xenografts were profiled as described previously using 244K human oligo microarrays (Agilent Technologies; ref. 22). The probes or genes for all analyses were filtered by requiring the lowest normalized intensity values in both samples and control to be more than 10. The normalized log2 ratios (Cy5 sample/Cy3 control) of probes mapping to the same gene (Entrez ID as defined by the manufacturer) were averaged to generate independent expression estimates. For Cy3 controls, we used Stratagene Human Universal Reference (23) enriched with equal amounts of RNA from the MCF7 and ME16C cell lines. Genes were median-centered and samples were standardized to zero mean and unit variance. To combine the BCM xenograft gene expression data with the UNC337 dataset, we estimated the technical bias from a subset of samples (n = 35) of the UNC337 dataset that were also profiled on the 244K platform. Intrinsic subtype classification was conducted in the combined BCM xenograft and UNC337 dataset using the PAM50 algorithm (24) and the 9-Cell Line Claudin-low Predictor (25; Table 2 and Supplementary Table S3). All Agilent microarray data are available in the University of North Carolina (UNC; Chapel Hill, NC) Microarray Database (https:// genome.unc.edu/) and have been deposited in the Gene Expression Omnibus (GEO) under the accession number GEO: GSE34412.

**Affymetrix gene expression analysis**

For most xenograft lines, Affymetrix gene expression arrays (U133 plus 2.0) were run on the first or second transplant generation (TG1 or TG2), and approximately every fifth transplant generation thereafter according to standard protocols recommended by Affymetrix. Arrays were scanned on an Affymetrix GeneChip 3000 Scanner (Agilent). Raw data were then analyzed by ArrayAnalyzer (Insightful Corporation) for normalization and expression estimation. All Affymetrix microarray data have been deposited in GEO under the accession number GEO:GSE46106. An Affymetrix expression summary file is included as Supplementary Table S4. Sample information for Affymetrix data are shown in Supplementary Tables S4 and S5 are available by download only from www.bcxenograft.org.

**Reverse-phase protein array expression analysis**

Xenograft-derived tissue was harvested and frozen at −80 °C before use. Small pieces of tumor tissue were added to 2 mL tubes with ceramic beads together with ice-cold lysis buffer containing 1% Triton X-100, 50 mmol/L Heps pH 7.4, 150 mmol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L EGTA, 100 mmol/L NaF, 10 mmol/L NaPPI, 10% glycerol, and 1 mmol/L Na3VO4. Complete Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktail (Roche Diagnostics). Protein supernatants were isolated as described previously (26) and protein concentration was determined by BCA assay (Pierce). Samples were diluted to a uniform protein concentration and then denatured in 1% SDS sample buffer for 5 minutes at 95 °C. Samples were stored at −80 °C until use. Reverse-phase protein array (RPPA) analysis was conducted as described previously (26, 27). Data were obtained for 161 antibodies. A logarithmic value reflecting the relative amount of each protein in each sample was generated.

---

**Table 1. Comparative xenograft take rate by transplant condition**

<table>
<thead>
<tr>
<th>Transplant condition</th>
<th>Host strain</th>
<th>Estradiol pellet</th>
<th>Human fibroblasts</th>
<th>Number of patients</th>
<th>Primary outgrowth rate (%)</th>
<th>Stable xenograft take rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Scid/Beige</td>
<td>–</td>
<td>–</td>
<td>38</td>
<td>18/38 (47.4)</td>
<td>1/38 (2.6)</td>
</tr>
<tr>
<td>2</td>
<td>Scid/Beige</td>
<td>+</td>
<td>–</td>
<td>70</td>
<td>28/70 (40)</td>
<td>15/70 (21.4)</td>
</tr>
<tr>
<td>3</td>
<td>Scid/Beige</td>
<td>+</td>
<td>+</td>
<td>29</td>
<td>13/29 (44.8)</td>
<td>1/29 (3.4)</td>
</tr>
<tr>
<td>4</td>
<td>NSG</td>
<td>+</td>
<td>–</td>
<td>32</td>
<td>10/32 (31.3)</td>
<td>6/32 (18.8)</td>
</tr>
</tbody>
</table>
**Table 2. Patient, Primary Tumor, and Xenograft Characteristics**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Xenograft line(s)</th>
<th>Xenograft PAM50 intrinsic subtype</th>
<th>Transplant condition</th>
<th>Patient ethnicity</th>
<th>Tumor source and treatment status</th>
<th>Patient tumor type</th>
<th>Estrogen receptor status</th>
<th>Progestrone receptor status</th>
<th>HER2 status</th>
<th>BRCA status</th>
<th>Patient nodal status</th>
<th>Patient metastatic site(s)</th>
<th>Xenograft metastasis rate to mouse lung (%)</th>
<th>Patient clinical treatment(s)</th>
<th>Patient clinical response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BCM-2147</td>
<td>Basal</td>
<td>1</td>
<td>AA</td>
<td>Pre, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>Brain</td>
<td>0</td>
<td>AC Res</td>
<td>Res</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>BCM-2277</td>
<td>Basal</td>
<td>1</td>
<td>Post, P.Br</td>
<td>IDC, Mmpap</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>7.1</td>
<td>–</td>
<td>0</td>
<td>AC, Doc</td>
<td>AC Sen, Doc Res</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>BCM-3107</td>
<td>Basal</td>
<td>2</td>
<td>Caucasian</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0</td>
<td>–</td>
<td>0</td>
<td>Doc Sen</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>BCM-3143</td>
<td>Basal</td>
<td>2</td>
<td>Caucasian</td>
<td>Post w/4, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>0</td>
<td>Lap + Taxane + Lap Res + Taxane + Trastuz Trastuz Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>BCM-3104</td>
<td>Basal</td>
<td>2</td>
<td>Post, P.Br</td>
<td>IDC</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0</td>
<td>–</td>
<td>0</td>
<td>AC Res</td>
<td>Res</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>BCM-3102</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>28.6</td>
<td>Brain</td>
<td>14.3</td>
<td>Xeloda (5FU) Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>BCM-3611</td>
<td>Basal</td>
<td>2</td>
<td>Caucasian</td>
<td>Pre, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>9.1</td>
<td>–</td>
<td>0</td>
<td>AC + GSI + Doc + Doc + GSI + GSI Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>BCM-3904</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0</td>
<td>–</td>
<td>0</td>
<td>AC + Doc + ISR + Doc + Doc + GSI Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>BCM-3906</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>0</td>
<td>–</td>
<td>0</td>
<td>Doc Sen</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>BCM-4004</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Pre, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>18.2</td>
<td>Brain</td>
<td>13.6</td>
<td>Das + Doc Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>BCM-4175</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>HER2 4</td>
<td>IDC</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>8.3</td>
<td>–</td>
<td>0</td>
<td>Das + Doc + GSI + Doc Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>BCM-3963</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Pre, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>21.4</td>
<td>Brain</td>
<td>28.6</td>
<td>Das + Doc + GSI + Doc Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>BCM-4169</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>13.6</td>
<td>–</td>
<td>0</td>
<td>Das + Doc + GSI + Doc Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>BCM-4195</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>8.3</td>
<td>–</td>
<td>0</td>
<td>Das + Doc + GSI + Doc Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>BCM-4195</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>21.4</td>
<td>–</td>
<td>0</td>
<td>Das + Doc + GSI + Doc Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>BCM-4400</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>28.6</td>
<td>–</td>
<td>0</td>
<td>Das + Doc + GSI + Doc Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>BCM-3887</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>BRCA1 + Brain</td>
<td>+</td>
<td>0</td>
<td>–</td>
<td>0</td>
<td>Doc Sen</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>BCM-3936</td>
<td>Basal</td>
<td>2</td>
<td>Baseline</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>66.7</td>
<td>–</td>
<td>0</td>
<td>AC + Doc + GSI + Doc Res + GSI Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>BCM-4013</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>36.4</td>
<td>–</td>
<td>0</td>
<td>Doc Sen</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>BCM-4169</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>HER2 4</td>
<td>IDC</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>33.3</td>
<td>–</td>
<td>0</td>
<td>ASI + Doc + Doc Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>BCM-4272</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Pre, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>0</td>
<td>–</td>
<td>0</td>
<td>AC + Pac + Trastuz Trastuz Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>BCM-4489</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Pre, P.Br IDC</td>
<td>IDC</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>66.7</td>
<td>–</td>
<td>0</td>
<td>Xeloda (5FU) + Pac Res + Xeloda Res + Pac Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>BCM-4489</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>66.7</td>
<td>–</td>
<td>0</td>
<td>Xeloda (5FU) + Pac Res + Xeloda Res + Pac Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>BCM-4400</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Pre, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>66.7</td>
<td>–</td>
<td>0</td>
<td>Xeloda (5FU) + Pac Res + Xeloda Res + Pac Res</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>BCM-4400</td>
<td>Basal</td>
<td>2</td>
<td>Hispanic</td>
<td>Post, P.Br IDC</td>
<td>IDC</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>66.7</td>
<td>–</td>
<td>0</td>
<td>Xeloda (5FU) + Pac Res + Xeloda Res + Pac Res</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Shaded area denotes xenografts derived from metastatic sites.

Abbreviations: AA, African American; AC, doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan); CWR, chest wall recurrence; Das, dasatinib; Doc, docetaxel; GSI, gamma secretase inhibitor; IDC, invasive ductal carcinoma; Lap, lapatinib; LCIS, lobular carcinoma in situ; Mmp, micropapillary; Met, metastatic disease; nd, not determined; nr, not reported; Pac, paclitaxel; Pre, pretreatment; Post, posttreatment; P.Br, primary breast; Res, < 30% response; Sen, ≥ 30% response; Trastuz, trastuzumab.
for analyses (28). Similarity of proteomic gene expression was evaluated using cluster analysis as well as by Pearson distance correlation analysis. An RPPA data summary is shown in Supplementary Table S6. Sample information for the RPPA data is shown in Supplementary Table S7, designated "rppa.info.final.color." Supplementary Tables S6 and S7 are available by download only from www bcm xenograft.org.

Sequenom analysis

PCR and extension primers for each gene were designed using Sequenom, Inc. Assay Design (Supplementary Table S8). PCR-amplified DNA was cleaned using EXO-SAP (Sequenom) primer extended by IPLEX chemistry, desalted using Clean Resin (Sequenom), and spotted onto Spectrochip matrix chips using a nanodispenser (Samsung). Chips were run in duplicate on a Sequenom MassArray MALDI-TOF MassArray system. Sequenom Typer Software and visual inspection were used to interpret mass spectra. Reactions where 8% or more of the resultant mass run in the mutant site in both directions were scored as positive (Supplementary Table S9).

Metastasis rates

To evaluate metastatic behavior, lungs and liver were harvested from each host mouse at each transplantation generation and evaluated grossly and histologically by H&E staining (3 sections per sample; Table 2; Supplementary Table S10).

Xenograft treatment response

Fresh xenograft tumor fragments of selected xenograft lines were transplanted into the cleared fat pad of recipient mice. When tumors reached a volume of approximately 200 mm³, mice were randomized and treated with either vehicle (9–10 mice), a single intraperitoneal injection of docetaxel (20 mg/kg; 3–9 mice), a single intraperitoneal injection of doxorubicin (3 mg/kg; 3–9 mice), or combined trastuzumab and lapatinib (10 mice) as described (29, 30), depending on the treatment the patient of origin received clinically. In some cases, patients were treated with chemotherapy in combination with an experimental targeted therapeutic (e.g., dasatinib or a gamma secretase inhibitor). In such cases, resistance to both agents in the patient and resistance to single agent in the xenograft were considered concordant. Tumor size was monitored twice weekly using calipers for a period of at least 2 weeks and growth curves plotted. Sensitivity was defined as 30% or more regression [Response Evaluation Criteria in Solid Tumors (RECIST) partial response or complete response]; resistance was defined as either less than 30% regression, stable disease, or continued growth (RECIST stable disease or progressive disease). Treatment responses in xenografts were compared with those of the primary tumor for concordance, and statistical significance of the difference between observed and expected concordance was evaluated by Fisher exact test. The degree of concordance above that expected by chance was evaluated using the kappa statistic.

Xenograft availability

Xenografts are available from the corresponding author for academic/nonprofit use on a cost recovery basis via a Material Transfer Agreement (mta@bcm.edu). Xenografts are maintained as viable frozen fragments (~1 mm³ frozen slowly at −80 °C and stored in liquid nitrogen; shipped on dry ice). Frozen fragments can be thawed rapidly and retransplanted. Fragments grow somewhat slower in the first transplantation after freezing, but revert to their characteristic growth pattern in subsequent transplant generations. All data presented in this report were derived from xenografts that had never been frozen.

Results

Establishment of xenografts using tumor fragments

Using SCID/Bg mice, 3 transplantation conditions were tested (Table 1 and Supplementary Table S1). Under transplantation condition 1 (unmanipulated hosts), primary tumor fragments representing 38 unique patients were implanted to a cleared fat pad to provide baseline take rates for comparison with experimental conditions. Upon harvest, 18 primary outgrowths were found after histologic evaluation (~47% primary outgrowth rate). Only one stably transplantable xenograft line (BCM-2147) was established (2.6% stable take rate).

Under transplantation condition 2 (estradiol supplementation only), primary tumor fragments representing 70 unique patients were implanted with 28 primary outgrowths obtained (40% primary outgrowth rate; Table 1). Fifteen patients yielded a stable xenograft (21.4% stable take rate), an approximately 8-fold increase above baseline, and consistent with recently published studies (1, 2, 5, 6, 8–12). Stable lines represented 12 "triple-negative" patients (Table 2), as well as 2 ER−PR−HER2+ patients (lines BCM-3143/3104 and BCM-3963/4.169), and one ER+PR+HER2− patient (line BCM-5097). Notably, 3 xenograft lines established under this condition were generated from 2 BRCA1 mutation carriers (patient 7, line BCM-4189) using ascites cells, as well as one line from an ER−PR−HER2+ patient (line BCM-5097). Notably, 3 xenograft lines established under this condition were generated from 2 BRCA1 mutation carriers (patient 7, line BCM-3887; and patient 17, lines BCM-4913 and BCM-5438), and one line was generated from a BRCA2 mutation carrier (patient 19, line BCM-5097; Table 2).

In addition to these fragment transplant lines, under condition 2 we also established a stable line from ascites cells from one patient (BCM-3561). Ascites cells and the resulting xenograft were triple negative, whereas the primary tumor in this patient was ER+PR+. We also established a line from one ER+PR−HER2− patient (line BCM-4189) using ascites cells, as well as one line from an ER−PR−HER2+ patient (line BCM-3613), from cells derived from pleural effusion fluid (Table 2).

Given the success of estradiol supplementation, we hypothesized that addition of immortalized normal human fibroblasts would enhance the take rate further (as shown previously for normal human mammary epithelium; 10). Under these conditions (condition 3), primary and stable take rates were similar to those under condition 1 (Table 1), with 13 of 29 patients yielding primary outgrowths (44.8%), but only 1 of 29 patients (3.4%) yielding a stable xenograft line (line BCM-2665; Table 2). Thus, rather than stimulating xenograft growth, the introduction of human fibroblasts derived from a normal patient was inhibitory to stable, but not primary, outgrowth. It is currently unclear why immortalized human fibroblasts would stimulate growth of normal human mammary tissue, but inhibit estradiol-enhanced growth of malignant tissue.
Overall, we found no significant differences in primary outgrowth rates between transplantation conditions using SCID/Bg host mice. However, there were significant differences for stable outgrowth rates, with condition 2 yielding more lines than condition 1 or 3 (OR: 11.0, 95% CI: 1.4–86.2, \( P = 0.023 \); OR: 8.3, 95% CI: 0.9–65.8, \( P = 0.045 \), respectively).

Given that condition 2 (estriol supplementation alone) provided our best stable take rate in SCID/Bg mice, these conditions were then tested in NOD/SCID/IL-2-receptor null (NSG) immunocompromised mice (condition 4: Table 1 and Supplementary Table S1). Of 32 patients tested, 10 (31.3%) yielded primary outgrowths, and 6 (18.8%) yielded stable xenograft lines. These included 4 triple-negative lines (BCM-4175, BCM-4195, BCM-4013, and BCM-5998), one ER–PR–HER2– line (BCM-4169), and one “triple-positive” ER+PR+HER2+ line (BCM-4888; Table 2). Primary outgrowth and stable take rate in NSG mice were not statistically different from those of SCID/Bg mice under condition 2 (logistic regression, \( P = 0.40 \) and \( P = 0.64 \), respectively).

In total, 32 stably transplantable xenograft lines were established representing 25 individual patients. Clinical features of the patient and primary tumor of origin for each stable xenograft line are shown in Table 2 and Supplementary Table S1. Of note, we established pretreatment/posttreatment xenograft pairs (BCM-2147/2,277; BCM-3611/3,824; BCM 3807/4400; BCM 3963/4169; and BCM-4272/4849), from 5 patients. With respect to ethnicity, we established xenografts representing 3 major ethnic groups, including 5 African American (AA) patients, 13 Hispanic patients, and 7 non-Hispanic Caucasian patients (Table 2). Finally, of the 22 patients used for fragment transplant, 11 patients were lymph node positive with 9 patients being node negative (2 not reported). Also included were 3 definitively metastatic patients (patients 23–25).

Regardless of the host strain used initially, all ER− lines were propagated in the cleared fat pad of SCID/Bg mice without humanizing fibroblasts or estradiol after the third transplant generation. All ER+ lines were propagated in the presence of estradiol supplementation; their estrogen dependency and sensitivity to hormonal therapies is currently under investigation.

**Xenograft take rate versus patient clinical characteristics**

To ensure that the difference in stable take rate across the transplantation conditions was not due to differences in patient characteristics, we compared across 4 different transplantation conditions using Fisher exact test. Clinical characteristics of patients were similar in the 4 groups used under the different transplantation conditions (Supplementary Table S1).

To evaluate which clinical characteristics correlated with high tumor take rate within each transplantation condition, the primary and stable xenograft outgrowth rates were summarized and compared across or between levels of each clinical characteristic using Fisher exact test. Under condition 2, the stable xenograft take rate was significantly different between grades 1 or 2 versus grade III invasive carcinoma, with only grade III tumors yielding stably transplantable xenografts. The stable take rate of ER+ (~52%) and PR+ (~37%) tumors was significantly higher than that of ER− (~2%) and PR− (~3%) tumors, respectively. The rate of stable transplantation across ethnic groups was not statistically different (Supplementary Table S1).

**Characteristics and stability of xenografts**

To evaluate whether stable xenografts retained histologic features and biomarker expression patterns consistent with the tumor of origin, we conducted comparative histologic and immunohistochemical analyses of outgrowths using clinically relevant biomarkers (ER, PR, and HER2), as well as TP53 (p53), EGFR(ErbB1), CK19, CK5, and Ki67, and compared biomarker status with the tumor of origin (Table 2 and Supplementary Table S3). Figure 1 shows all xenograft lines for which matched primary patient samples were available for histologic comparison \((n = 20);\) unmatched xenograft lines are shown in Supplementary Fig. S2. In all cases, patients retained their invasive histologic phenotype as xenografts. Tumor cellularity was estimated to exceed 80% in all xenografts (Fig. 1). Figure 2 shows 5 representative xenografts and their matched primary breast cancer with respect to the range of biomarker expression observed (biomarker expression fully summarized in Supplementary Table S3). Triple-negative xenografts could be either CK19− (e.g., BCM-3807) or CK19+ (e.g., BCM-5156). All ER+ and/or HER2+ xenografts generated were CK19+. In all cases that could be compared, each xenograft retained the biomarker status observed in the patient. Furthermore, all lines tested retained their histologic phenotype and biomarker expression patterns of the tumor of origin over multiple passages (3 representative xenografts are shown in Supplementary Fig. S3). One xenograft (BCM-3807/4400) was found to grow as a fluid-filled mass at each transplant generation. The presence of this yellowish fluid was a clinical feature of the tumor of origin in the patient.

**Metastatic behavior of xenografts**

Because 18 of the 32 xenograft lines were derived from 14 patients that were either lymph node positive, or had metastatic breast cancer at other sites (brain, abdominal ascites, pleural cavity; Table 2), we evaluated host mice for the presence of liver and lung metastases. Neither circulating tumor cells, nor lymph node, brain or bone metastases, were examined in this study. Lungs and livers of xenograft-bearing mice were sampled at each transplantation generation and screened by histologic examination. In xenograft lines representing 12 of 25 patients (48%), stable xenograft lines (including 2 ER− xenograft lines) showed single or multiple foci of metastatic mammary adenocarcinoma as pulmonary metastases (Fig. 3; Table 2 and Supplementary Table S10). No liver metastases were detected. The presence of lung metastasis in mice did not necessarily correlate with nodal/metastatic status in the patient of origin (Table 2 and Supplementary Table S10).

**Intrinsic subtype classification**

To determine the tumor subtype that these xenograft lines best resemble, we conducted global gene expression analyses using 244K human oligo microarrays (Agilent Technologies; ref. 22). Using approximately 1,900 intrinsic gene list (24), we
coclustered the xenografts samples with the UNC337 dataset that has an appropriate representation of all the intrinsic molecular subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like and Claudin-low; ref. 25). Xenografts clustered with either the Basal-like or the HER2-enriched tumors and they did not cluster as a single group (Fig. 4A and B). Interestingly, while

![Figure 1. Comparisons of representative patient biopsies and their resulting xenografts. H&E-stained sections. Patient biopsies are depicted in the left column; corresponding xenograft samples are depicted in the right column. Scale bar, 50 μm.](image-url)
most (3 of 4) HER2\(^+\) samples clustered with the HER2-enriched tumors. HER2\(^+\) BCM-3143/3104 line clustered with the Basal-like tumors. Conversely, 3 HER2\(^-\) xenografts (BCM-4175, BCM-4189, and BCM-3561) were identified as HER2-enriched. This observation is concordant with recent studies in human tumors showing that not all HER2\(^+\) tumors are HER2-enriched by gene expression, and that not all HER2\(^-\) enriched tumors are HER2\(^+\) (31). Regarding ER\(^+\)/HER2\(^-\)/C0 xenograft lines, BCM-4189 was identified as HER2-enriched and BCM-5097 (also PR\(^+\)) was identified as Basal-like. This observation is also concordant with a recent study showing that a subset of poor prognosis ER\(^+\) tumors can be identified as Basal-like (32). Finally, identical intrinsic subtype calls were obtained when the PAM50 classifier was applied to the xenograft samples (Table 2).

**Stability of xenografts with respect to their transcriptome, proteome, and genome**

To show whether transplantable xenografts were stable at the transcriptome level, and to show whether xenografts established using pretreatment biopsies were consistent with xenografts established with posttreatment biopsies, we conducted Affymetrix gene expression analysis using a majority of the xenograft lines, with arrays conducted roughly every fifth transplant generation whenever available. Within a given xenograft line, the transplant generations invariably clustered together thus showing stability at the level of gene expression across at least five transplant generation (Fig. 5A). In addition, lines established from both initial pretreatment fragments (I) as well as posttreatment fragments (P) from the same patient also clustered together (Fig. 5A). The within patient and between patients Pearson correlation coefficients are depicted in Fig. 5B showing the within patient correlations to be consistently higher than the between patients correlations.

To show whether stably transplantable xenografts were also stable at the proteome level, we conducted RPPA expression analysis on xenografts representing all 25 patients using 161 antibodies. For those xenografts having samples representing multiple transplant generations, the related samples invariably clustered together thus showing stability at the level of the proteome using both hierarchical clustering and Pearson correlation coefficient comparison methods (Fig. 5C and D). In addition, lines established from both initial pretreatment fragments (I) as well as posttreatment fragments (P) from the same patient also invariably clustered together. As with the Affymetrix analysis, within patient correlations were consistently higher than between patient correlations.

To estimate whether xenografts were genomically stable and to identify single nucleotide polymorphisms (SNP) that may be relevant to xenograft biology, we conducted Sequenom analysis of SNPs for 155 known polymorphisms in 32 cancer-relevant genes (Supplementary Table S8) using each xenograft line, with each line represented at multiple transplant generations whenever possible. No tumor suppressor genes were evaluated in this study. A majority of the SNPs detected were in the PIK3CA gene (lines BCM-3613, BCM-3807/4400, and BCM-4888; Supplementary Table S9) each showing a unique genetic alteration. However, a potentially activating SNP in c-Met (N375S_A1124G) was identified in both BCM-2147/2277 and BCM-3143/3104, with BCM-2277 showing an additional KRAS polymorphism (Q61LPR_A182TCG) relative to BCM-2147.

![Figure 2. Biomarker expression in representative xenografts. Five representative patient samples showing retained biomarker status as xenografts. Xenograft line designations are shown above the column to which they apply. Biomarker designations are shown to the left of the row to which they apply. Insets show the corresponding biomarker status in the tumor of origin. Scale bar, 50 \(\mu\)m.](cancerres.aacrjournals.org)
that was either recovered as a function of sampling, or potentially selected for, or acquired, as a function of AC treatment. One activating AKT1 mutation (E17K_G49A) was identified in BCM-4175. Thus, these transplantable xenograft lines are genotypically stable across multiple transplant generations with respect to the genes represented in this assay.

Figure 3. Histologic analysis of lung metastases. Twelve xenograft lines showing lung metastases are shown. Insets show higher magnification images of the metastatic lesion. Scale bar, 50 μm.
Patient/xenograft treatment response concordance

To evaluate biologic relevance and translational use, we tested treatment responses of 11 xenograft lines derived from patients for whom we have a total of 13 observed clinical treatment responses to essentially the same drug. Twelve of 13 xenograft responses matched the corresponding clinical responses (Supplementary Table S11; Supplementary Fig. S4). The sole discordant result was in a xenograft line derived from ascites. The ascites cells were resistant to paclitaxel in the patient, but were modestly sensitive to docetaxel when grown as a xenograft (33% decrease in tumor volume over the observation period). As most xenograft lines were resistant to the therapies used, one would expect about 60% concordance entirely by chance. However, our observed concordance of 92% was substantially higher (\( k = 0.75, P = 0.003 \)), and there was a significant association between the xenograft and patient-derived results (Fisher exact test, \( P = 0.04 \)).

Discussion

The mouse mammary gland model derives its experimental power, in part, from the ability to transplant mammary epithelium from one animal to another. Transplantation allows one to expand normal, genetically modified, or neoplastic tissue into multiple hosts. With respect to therapeutic studies, tissue expansion by transplantation allows study of the in vivo effects of multiple agents on the behavior of the epithelium. In contrast, such studies are not possible in human patients, and experimental analysis of the human mammary gland and breast cancers has been limited by the lack of a suitable transplantation model in which malignant xenografts grow efficiently and tumor biology is, to the extent possible, faithful to the biology of the tumor of origin in the patient. In this study, we show that the SCID/Bg and NSG immunocompromised mice are relatively permissive for growth of malignant tissue and allow the establishment of stably transplantable "triple-negative" HER2 \(^{-} \) and ER \(^{-} \) xenograft lines from an ethnically diverse patient population. These xenografts are histologically and immunohistochemically indistinguishable from the tumor of origin, show comparable treatment responses, and are transcriptionally, translationally, posttranslationally, and genomically, stable across multiple transplantation generations.

There have been numerous attempts to generate transplantable xenografts over the last 3 decades. Historically, stable take rates for xenografts were low (~10%, or less), but have improved in more recent studies (1, 2, 5, 6, 8–10, 33–40). Our stable take rate under condition 2 (estradiol supplementation in SCID/Bg mice) was approximately 21%, with a statistically similar take rate observed in NSG mice (~19%). Thus, the rate we obtained in SCID/Bg and NSG mice is at the high end of the historical range. Similarly, high per patient take rates (10 of 42 patients; ~24%) were shown recently by DeRose and colleagues (12) using tissue fragments coated in Matrigel and implanted into the intact fat pad of either NOD/SCID or NSG mice supplemented with estradiol. An exceptionally high take rate (~40%) was also obtained by Kabos and colleagues (10 of 27 patients; 37%; ref. 15) using tissue fragments or metastatic cells (pleural fluid/ascites) coated in Matrigel and implanted into the intact fat pad of either NOD/SCID or NSG mice supplemented with estradiol. Elevated take rates in advanced tumors in our studies are consistent with the apparent elevated tumor-initiating cell (TIC; also known as cancer stem cell) frequency in high-grade tumors relative to low-grade tumors (41). However, these data could also be explained by lack of one or more factors required for growth of low-grade tumors in the SCID/Bg and NSG mice rather than a decreased TIC frequency per se. Our data are also consistent with these recent studies showing that estradiol supplementation stimulates growth of breast cancer...
xenografts, including ER− xenografts (12, 15, 42, 43). This stimulatory effect of estradiol supplementation on ER-negative tumor growth is, at least in part, due to an ERα-mediated effect on bone marrow-derived myeloid cells that promote angiogenesis and tumor growth (44).

Despite the observation that approximately 80% of all breast cancers in women are ER+, relatively few cell line or xenograft models are available. Recently, a few groups have succeeded in generating ER− xenograft lines (12, 15). In this work, we were also able to generate 3 new stably outgrowthable ER+ xenograft lines, 2 of which are metastatic to the mouse lung. Unfortunately, the rate of stable outgrowth was still low relative to triple-negative tumors, and perhaps due to the omission of Matrigel coating in our protocol, we did not recover stable lines representing the luminal subtypes. Thus, efficient establishment of ER+ xenografts will require further optimization. One potential method is via cotransplantation with mesenchymal stem cells, which were shown recently to enhance mammosphere formation in vitro (45), and to stimulate growth and metastasis of established xenografts in vivo (12, 46–48). Alternatively, some mouse proteins [e.g., prolactin, hepatocyte growth factor, interleukin (IL)-6] do not activate their human receptor counterparts (48–50). Thus, tissue-appropriate expression of one or more of these human ligands as transgenes in an immunocompromised mouse background may be necessary to stimulate ER− xenograft growth fully.

Two important features of a useful experimental model are the degree to which the experimental model faithfully recapitulates the tumor in the patient of origin and the stability of the experimental model over time. In this study, all xenografts showed biologic consistency with the tumor of origin both at the level of histology, and with respect to several clinically (ER, PR, HER2, Ki67) and biologically (TP53, EGFR, CK5/6, CK19) relevant biomarkers. With respect to the issue of stability over time, all xenografts for which Affymetrix RNA expression patterns or RPPA protein expression patterns were determined for multiple transplantation generations showed a high degree of stability with respect to gene expression at the mRNA and protein level, including posttranslational modifications. Unfortunately, it was not possible to evaluate the degree to which the

Figure 5. Transcriptome and proteome stability. Xenograft lines are phenotypically stable over multiple transplant generations with respect to gene expression by Affymetrix microarray and RPPA. A, hierarchical cluster analysis using all probesets with detectable expression. Xenograft designation (BCM-####), and transplant generation number (TG#) are shown for each branch of the dendrogram. Patient of origin/xenograft association is designated by color. B, box and whisker plot of Pearson correlation distances within patient and between patients. C, hierarchical cluster analysis using 161 antibodies in RPPA. Xenograft designations are as shown in A. D, box and whisker plot of Pearson correlation distances within patient and between patients.
xenograft transcriptome or proteome were consistent with those of the tumor of origin because patients were enrolled in ongoing clinical trials and their array data could not yet be released, and remaining banked tissue was not sufficient to run RPPA without exhausting the sample entirely.

In addition to the molecular diversity shown by this collection of xenografts, the lines established represent diversity with respect to the ethnic groups, as well as metastatic behavior. Of particular interest is the finding that the 2 of the 3 ER+ breast cancer xenografts established were metastatic from the orthotopic site. Similar results were recently obtained by DeRose and colleagues (12). In contrast, we know of only one ER+ metastasis model in cell lines, a metastatic derivative of MCF7 developed recently (51). Thus, these models should be useful in evaluating ethnic differences in tumor behavior, as well as evaluating therapeutic agents that might in particular influence metastatic behavior, particularly of ER+ breast cancer.

Perhaps, the most critical issue not addressed fully to date is the question of whether PDX models respond to a given treatment in a manner similar to the tumor of origin in the patient. This issue is important not only to establish relevance as experimental models, but particularly from a clinical/translational standpoint. If, in fact, the PDX models respond similarly to a given agent, it should be possible to identify predictive indicators of response that may ultimately be useful clinically. Furthermore, there should be relevant biologic underlying PDX treatment resistance that can be exploited to improve treatment clinically. A previous study evaluating 7 xenografts showed an observed concordance of 71% versus an expected concordance of 47% (9). However, statistical significance was not shown using this sample size ($\kappa = 0.46$, $P = 0.08$) in our study, a majority of xenograft lines tested showed qualitatively identical treatment responses as the corresponding patient treated with a similar or identical agent, and statistical significance was achieved using this increased sample size. While the lack of a functional immune system may ultimately be shown to alter treatment responses to some agents, the observation that xenograft lines responded to 2 common chemotherapeutics in a qualitatively identical manner as the patient of origin strongly suggests that results obtained in 'mouse clinical trials’ will be generally relevant to patients.

Disclosure of Potential Conflicts of Interest
M.T. Lewis and J.C. Chang are Founding Partners in StemMed Ltd. C.M. Perou is an equity stock holder in University Genomics and BioClassifier LLC and is listed as an inventor on a patent application on the PAM50 assay. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: X. Zhang, R. Schiff, P. Zuloaga, M.F. Rimawi, J.C. Chang, M.T. Lewis
Development of methodology: X. Zhang, L. Wiechmann, R. Schiff, J. Huang, M.F. Rimawi, G.B. Mills, J.C. Chang, M.T. Lewis
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): X. Zhang, A. Prat, S. Claerhout, L.E. Dobrolecki, I. Petrovic, Q. Lai, M.D. Landis, R. Schiff, M. Giuliani, H. Wong, S.W. Fuqua, A. Contreras, J. Huang, A.C. Pavlick, A.M. Froelich, M.F. Rimawi, C.M. Perou, J.C. Chang, M.T. Lewis
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): X. Zhang, A. Prat, L.E. Dobrolecki, I. Petrovic, R. Schiff, J. Huang, M.F. Wu, A. Tsimelzon, S.G. Hilsenbeck, E.S. Chen, C.A. Shaw, C.M. Perou, J.C. Chang, M.T. Lewis
Writing, review, and/or revision of the manuscript: X. Zhang, A. Prat, S. Claerhout, L.E. Dobrolecki, M.D. Landis, R. Schiff, C. Gutierrez, S.G. Hilsenbeck, M.F. Rimawi, C.M. Perou, G.B. Mills, J.C. Chang, M.T. Lewis
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): X. Zhang, S. Mao, A.C. Pavlick, E.S. Chen, M.F. Rimawi, G.B. Mills, J.C. Chang, M.T. Lewis
Study supervision: J.C. Chang, M.T. Lewis

Acknowledgments
The authors thank Dr. Charlotte Kuperwasser for generously providing the normal human fibroblast line used in this study.

Grant Support
This work was supported in part by The Breast Cancer Research Foundation, The Emma Jacobs Clinical Breast Cancer Fund, The Helis Foundation, The Susan G. Komen Foundation, Cancer Fighters of Houston, BCM Cancer Center Grant P30-CA125123, BCM Breast Cancer SPORE P50 CA50183, UNC Breast Cancer SPORE P50 CA58223, National Cancer Institute (NCI) NIH Grant RO1 CA112305, NIH/NCI Grant U54 CA199196, Cancer Prevention Research Institute of Texas Grant RP101251, CA16672 (RPPA core), and PO1 CA38195 from NCI, K12-5611B through The University of Texas Health Science Center from NIH, and US Army Medical Research and Materiel Command. Grants DAMD17–01–0122 and W81XWH-04-1-0468. G.B. Mills is supported by a Stand Up to Cancer Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation, SU2C-AACR-DT0289.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 6, 2012; revised April 24, 2013; accepted May 10, 2013; published OnlineFirst June 4, 2013.

References


A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models

Xiaomei Zhang, Sofie Claerhout, Aleix Prat, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-4081

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/05/31/0008-5472.CAN-12-4081.DC1

Cited articles
This article cites 51 articles, 19 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/15/4885.full#ref-list-1

Citing articles
This article has been cited by 14 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/73/15/4885.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.